Study of body markers in recurrent glioblastoma
Part of Cancer clinical trials.
This study looks at special markers in the blood and tumors of people whose glioblastoma has come back. It may help doctors understand why the cancer returns and how to treat it better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You had surgery for both your first glioblastoma and when it came back (recurrence) at the University Hospital of Bordeaux between 2005 and 2023.
- You have not received chemotherapy or other systemic treatment for a different type of cancer (not glioblastoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
This trial collects tumor samples to study what causes glioblastoma to return. It may help scientists find better treatments.
This study analyzes tissue and health-related biological data from people with glioblastoma to learn what’s happening in the tumor. The results may help improve future ways to understand and treat glioblastoma using advanced computer analysis.
This study looks at how different treatments work for people with advanced brain or spinal cord tumors that have come back. It helps doctors learn more about these tumors and how to better treat them.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
Hear when a new Relapsed Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.